HIE study shows reductions in test duplication

Use of the health information exchange (HIE) has had a significant effect on the duplication of tests, according to researchers at the Brookings Institution in cooperation with HEALTHeLINK.

The researchers conducted a pilot study to examine the impact of the use of HIE technology on reducing laboratory tests and radiology examinations in emergency departments (EDs) at three area hospitals. The results of the pilot were published in the Journal of the American Medical Informatics Association and the Center for Technology Innovation at Brookings.

HEALTHeLINK’s clinical liaisons shadowed physicians within the EDs at Kenmore Mercy Hospital, Erie County Medical Center and Buffalo General Medical Center. A total of 1,450 patients were seen in these three EDs during the pilot which found a reduction in ordering of laboratory tests and radiology exams. 

In one ED, access to patients’ information within HEALTHeLINK, led to a 52 percent reduction in the estimated number of laboratory tests and a 36 percent reduction in the estimated number of radiology exams. The other two EDs experienced similar reductions.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.